title: Protein expression and methylation of MGMT, a DNA repair gene and their correlation with clinicopathological parameters in invasive ductal carcinoma of the breast.
abstract: Epigenetic mechanisms such as DNA methylation are being increasingly recognized to play an important role in cancer and may serve as a cancer biomarker. The aim of this study was to evaluate the promoter methylation status of MGMT (O6-methylguanine-DNA methyltransferase) and a possible correlation with the expression of MGMT and standard clinicopathological parameters in invasive ductal breast carcinoma patients (IDC) of Kashmir. Methylation-specific PCR was carried out to investigate the promoter methylation status of MGMT in breast tumors paired with the corresponding normal tissue samples from 128 breast cancer patients. The effect of promoter methylation on protein expression in the primary breast cancer and adjacent normal tissues was evaluated by immunohistochemistry (n = 128) and western blotting (n = 30). The frequency of tumor hypermethylation was 39.8 % and a significant difference in methylation frequency among breast tumors were found (p < 0.001) when compared with the corresponding normal tissue. Immunohistochemical analysis showed no detectable expression of MGMT in 68/128 (53.1 %) tumors. MGMT promoter methylation mediated gene silencing was associated with loss of its protein expression (rs = -0.285, p = 0.001, OR = 3.38, 95 % CI = 1.59-7.17). A significant correlation was seen between loss of MGMT and lymph node involvement (p = 0.030), tumor grade (p < 0.0001), loss of estrogen receptors (ER; p = 0.021) and progesterone receptors (PR) (p = 0.016). Also, MGMT methylation was found to be associated with tumor grade (p = 0.011), tumor stage (p = 0.009), and loss of ER (p = 0.003) and PR receptors (p = 0.009). To our knowledge, our findings, for the first time, in Kashmiri population, indicate that MGMT is aberrantly methylated in breast cancer and promoter hypermethylation could be attributed to silencing of MGMT gene expression in breast cancer. Our data suggests that MGMT promoter hypermethylation could have a potential function as molecular biomarker of breast oncogenesis. Also, based on their predictive value of response to therapy, the immunohistochemical evaluation and interpretation of MGMT may also help in future to establish therapeutic strategies for patients with breast cancer.
authors.affiliation: Department of Biochemistry, Faculty of Biological Science, University of Kashmir, Srinagar, J&K, India, 190006, asiaf29@gmail.com.
authors.forename: Asia
authors.initials: A
authors.lastname: Asiaf
authors.forename: Shiekh Tanveer
authors.initials: ST
authors.lastname: Ahmad
authors.forename: Ajaz Ahmad
authors.initials: AA
authors.lastname: Malik
authors.forename: Shiekh Aejaz
authors.initials: SA
authors.lastname: Aziz
authors.forename: Zubaida
authors.initials: Z
authors.lastname: Rasool
authors.forename: Akbar
authors.initials: A
authors.lastname: Masood
authors.forename: Mohammad Afzal
authors.initials: MA
authors.lastname: Zargar
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000096:biosynthesis / Q000235:genetics*; D001943:Breast Neoplasms / Q000235:genetics* / Q000473:pathology; D018270:Carcinoma, Ductal, Breast / Q000235:genetics* / Q000473:pathology; D019175:DNA Methylation / Q000235:genetics*; D015254:DNA Modification Methylases / Q000096:biosynthesis / Q000235:genetics*; D045643:DNA Repair Enzymes / Q000096:biosynthesis / Q000235:genetics*; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D011401:Promoter Regions, Genetic; D025521:Tumor Suppressor Proteins / Q000096:biosynthesis / Q000235:genetics*
chemical_list: D014408:Biomarkers, Tumor; D025521:Tumor Suppressor Proteins; D015254:DNA Modification Methylases; C515491:MGMT protein, human; D045643:DNA Repair Enzymes
references.citation: Indian J Exp Biol. 2006 Feb;44(2):115-9
references.pmid: 16480176
references.citation: Nat Struct Mol Biol. 2004 Aug;11(8):714-20
references.pmid: 15221026
references.citation: Mol Carcinog. 1999 Feb;24(2):85-9
references.pmid: 10078935
references.citation: Life Sci. 2010 Jul 17;87(3-4):83-91
references.pmid: 20470789
references.citation: Proc Natl Acad Sci U S A. 1996 Jul 9;93(14):6941-6
references.pmid: 8692923
references.citation: Hum Pathol. 2006 Aug;37(8):989-99
references.pmid: 16867861
references.citation: Cancer Res. 2010 Jul 15;70(14):6047-58
references.pmid: 20587515
references.citation: Clin Cancer Res. 1996 May;2(5):805-10
references.pmid: 9816234
references.citation: Oncol Rep. 2012 May;27(5):1630-8
references.pmid: 22159596
references.citation: Jpn J Clin Oncol. 2005 Mar;35(3):121-5
references.pmid: 15741301
references.citation: Nat Rev Cancer. 2008 Mar;8(3):193-204
references.pmid: 18256616
references.citation: Histopathology. 2013 Nov;63(5):713-25
references.pmid: 24004112
references.citation: J Clin Oncol. 2005 May 1;23(13):2903-10
references.pmid: 15753461
references.citation: Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6189-93
references.pmid: 15448006
references.citation: N Engl J Med. 2008 Mar 13;358(11):1148-59
references.pmid: 18337604
references.citation: Cancer Res. 2000 May 1;60(9):2368-71
references.pmid: 10811111
references.citation: Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):5998-6005
references.pmid: 15447983
references.citation: Breast Cancer Res. 2010;12 (1):R3
references.pmid: 20056007
references.citation: Cancer Res. 1990 Oct 1;50(19):6119-29
references.pmid: 2205376
references.citation: Semin Cancer Biol. 2009 Jun;19(3):165-71
references.pmid: 19429480
references.citation: Biochem Cell Biol. 2005 Aug;83(4):429-37
references.pmid: 16094446
references.citation: Ann Surg Oncol. 2001 Dec;8(10):807-16
references.pmid: 11776495
references.citation: Am J Clin Pathol. 2002 Sep;118(3):408-17
references.pmid: 12219783
references.citation: DNA Repair (Amst). 2007 Aug 1;6(8):1155-60
references.pmid: 17482895
references.citation: Int J Cancer. 2005 Aug 20;116(2):174-81
references.pmid: 15800905
references.citation: J Clin Oncol. 2006 Sep 10;24(26):4262-9
references.pmid: 16908936
references.citation: Cancer. 1990 Oct 15;66(8):1663-70
references.pmid: 2208020
references.citation: J Pathol. 2003 Oct;201(2):213-20
references.pmid: 14517838
references.citation: Breast Cancer Res Treat. 2012 Jul;134(1):131-7
references.pmid: 22228432
references.citation: Clin Cancer Res. 2004 Mar 15;10(6):2052-7
references.pmid: 15041725
references.citation: Cancer Chemother Pharmacol. 1996;37(6):547-55
references.pmid: 8612308
references.citation: Nat Rev Cancer. 2004 Apr;4(4):296-307
references.pmid: 15057289
references.citation: Prog Nucleic Acid Res Mol Biol. 1995;51:167-223
references.pmid: 7659775
references.citation: J Cancer Res Ther. 2012 Jul-Sep;8(3):389-93
references.pmid: 23174720
references.citation: DNA Repair (Amst). 2007 Aug 1;6(8):1079-99
references.pmid: 17485253
references.citation: Nucleic Acids Res. 2007;35(6):e41
references.pmid: 17289753
references.citation: N Engl J Med. 2005 Mar 10;352(10 ):997-1003
references.pmid: 15758010
references.citation: Anticancer Res. 2009 Oct;29(10):3759-68
references.pmid: 19846906
references.citation: Curr Opin Pharmacol. 2006 Aug;6(4):355-63
references.pmid: 16777483
references.citation: Oncol Lett. 2014 Jun;7(6):1778-1784
references.pmid: 24932232
references.citation: Exp Mol Pathol. 2012 Feb;92 (1):20-6
references.pmid: 22019339
references.citation: Cancer Res. 1999 Feb 15;59(4):793-7
references.pmid: 10029064
references.citation: Int J Cancer. 2006 May 1;118(9):2168-71
references.pmid: 16331610
references.citation: Clin Cancer Res. 2006 Nov 15;12(22):6591-3
references.pmid: 17121875